HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.

Abstract
In a phase II study, 77 patients with metastatic breast cancer were treated with pirarubicin, 70 mg/m2 iv every 3 weeks. Most of them had received prior hormonal (n = 39) and/or chemotherapeutic drug treatment for advanced disease, including anthracycline-containing regimens in 17. After a median of 5.5 treatment cycles (range 1-14), objective tumor response was seen in 22/71 (31%) evaluable patients (4CR, 18 PR). Stable disease occurred in 34 (48%) patients, whereas the tumor progressed in 15 (21%). Significant hematologic toxicity (WHO grade III-IV) requiring interval and/or dose adjustments was observed in 41 (58%) patients. Other treatment-related side effects were generally mild, and included alopecia in 52 (73%), nausea and/or emesis in 50 (70%), and stomatitis and diarrhea in 3 patients each. There was no treatment-related death, nor was there any evidence of cardiac toxicity thus far. In summary, the early results of this trial suggest that pirarubicin is an active and rather well tolerated drug in pretreated patients with advanced breast cancer.
AuthorsW Scheithauer, H Samonigg, D Depisch, J Schüller, H Hausmaninger, J Wiegele, C Zielinsky, H Stöger, K Haider, P Preis
JournalInvestigational new drugs (Invest New Drugs) Vol. 8 Issue 2 Pg. 207-10 (May 1990) ISSN: 0167-6997 [Print] United States
PMID2384308 (Publication Type: Journal Article)
Chemical References
  • Doxorubicin
  • pirarubicin
Topics
  • Adult
  • Aged
  • Alopecia (chemically induced)
  • Breast Neoplasms (drug therapy)
  • Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Intravenous
  • Leukopenia (chemically induced)
  • Male
  • Menopause
  • Middle Aged
  • Nausea (chemically induced)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: